U.S.-based companies are dragging down the major stock market indexes. But getting caught up in short-term market movements ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.

The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA ...

It’s a little known fact outside the growing community: peat is ubiquitous in producing the fruits and vegetables we eat.

His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx. The 2024 End-of-Year Report showcases significant changes in the tax landscape, indicating additional ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA Approves A New, Non-Opioid Painkiller In January, the Food and Drug Administration approved a new pain medicine called Journavx (suzetrigine), made by Vertex Pharmaceuticals. It's the ...